Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Amazon Explores AI Content Marketplace With Media Publishers 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
CHESTERBROOK, Pa., March 14, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Oppenheimer & Company 28th Annual Healthcare Conference on Wednesday, March 21, 2018, at 2:45 p.m. EDT in New York, NY.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO™ (oliceridine) Injection for the management of moderate-to-severe acute pain. OLINVO has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
